Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous memory cytokine-enriched natural killer cells

A population of cryopreserved, autologous CD56-positive memory cytokine-enriched natural killer (NK) cells (m-ceNKs), armed with NK cell-activating surface receptors, with potential immunomodulating and antitumor activities. Autologous NK cells are pre-activated ex vivo with a cytokine cocktail, which induces the differentiation of the NK cells into immune-memory m-ceNKs, which possess a unique phenotype. The pretreated NKs exhibit enhanced cytotoxicity and increased interferon-gamma (IFN-g) production. Upon administration, the autologous m-ceNKs may recognize and kill tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous cytokine-induced memory-like NKs
autologous m-ceNK cells
autologous M-CENKs
autologous memory cytokine-enhanced NK cells
autologous memory cytokine-enriched NK cells
m-ceNK
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search